Improving Chronic Disease Outcomes For Indigenous Australians: Causes,Interventions, System Change
Funder
National Health and Medical Research Council
Funding Amount
$8,788,853.00
Summary
Diabetes and cardiovascular diseases occur in epidemic proportions among Indigenous Australians, with very early age of onset and high rates of preventable complications. This Program will bring together a multi skilled team of researchers with Indigenous partners to better understand the development of these conditions, and to guide the development of diet, lifestyle, clinical and health system interventions in order to minimise their adverse impacts and improve health overall.
Linking Lifestyle And Molecular Biology To Inform Precision Public Health For Major Cancers
Funder
National Health and Medical Research Council
Funding Amount
$8,487,111.00
Summary
The Program of research seeks to increase our understanding of cancer risk. We will use our large collections of population and family-based datasets to conduct innovative analyses, improving our understanding of the roles that genetic, epigenetic and lifestyle factors play in our risk of breast, colorectal and prostate cancer. This information should allow us to better predict a person’s cancer risk, enabling public health interventions, such as screening, to be delivered more effectively and e ....The Program of research seeks to increase our understanding of cancer risk. We will use our large collections of population and family-based datasets to conduct innovative analyses, improving our understanding of the roles that genetic, epigenetic and lifestyle factors play in our risk of breast, colorectal and prostate cancer. This information should allow us to better predict a person’s cancer risk, enabling public health interventions, such as screening, to be delivered more effectively and economically to those most at risk.Read moreRead less
Improving The Health Of People With Problematic Drug Use: Hepatitis C And Drug Dependence
Funder
National Health and Medical Research Council
Funding Amount
$9,060,140.00
Summary
Problematic drug use is the major risk factor to health among Australians aged 15-49 years. The dual harms of drug dependence and hepatitis C virus (HCV) faced by people who use drugs compel improved drug dependence management and HCV prevention and treatment. This Program Grant will improve the lives of people with problematic drug use by investigating health impacts of drug use and evaluating new strategies for managing drug dependence and eliminating HCV among people who use drugs.
ADVANCING THE EVIDENCE BASE FOR CARE AND POLICY IN PRIORITY HEALTH AREAS
Funder
National Health and Medical Research Council
Funding Amount
$11,195,727.00
Summary
This program will improve health care and policy through clinical trials research and better methods for combining trial evidence. The team will tackle priority health areas to reduce death and serious disability: in particular in cancer, cardiovascular disease, diabetes, obesity and neonatal diseases. The program team includes clinicians, epidemiologists, trialists, biostatisticians, and health economists and collaborative networks of clinical investigators in each disease area.
Uncovering The Basis Of Inflammatory And Immunodeficiency Diseases
Funder
National Health and Medical Research Council
Funding Amount
$15,718,075.00
Summary
A world-class team from 3 institutions, spanning disciplines of clinical and experimental immunology, therapeutics, signalling and genetics, will identify how immune and inflammatory responses are controlled in both health and disease. The major outcomes of this work will be the generation of new knowledge, concepts and approaches to diagnose, prevent and treat the major human health problems of autoimmune diseases, inflammation, allergy and immunodeficiency.
Hepatitis C affects a quarter of a million Australians, causing insidious but progressive liver disease which culminates in liver failure or cancer. There is no vaccine and prevention programs have limited effectiveness, but new antiviral therapies now offer high rates of cure. This Program will evaluate strategies to improve the health of those affected and prevent new infections by better understanding of the virus and the body’s immune response, including scarring and liver cancer formation.
Generating The Evidence To Control Cancer And Optimise Outcomes
Funder
National Health and Medical Research Council
Funding Amount
$6,564,341.00
Summary
Our Program addresses the public health aspects of common cancers, particularly cancers of the skin and gynaecological tracts. Each year in Australia, nearly 400,000 people are treated for skin cancer, and more than 3,500 women develop ovarian or uterine cancer. Our aims are first, to understand how we might prevent these cancers in the future; second, to enhance diagnosis of these cancers; and third, to improve the survival and quality of life for people who are diagnosed with these cancers
Tropical Diseases: Translating Discoveries Into Better Health
Funder
National Health and Medical Research Council
Funding Amount
$19,803,660.00
Summary
Major progress being made in control of many infectious diseases occurring in tropical areas, including malaria worms and the bacteria that causes strep throat. However, currently available tools will not permit their full control or elimination. This program is aimed to improve understanding of these diseases and to develop the much needed tools that will be required for their elimination.
Novel Approaches To The Prevention And Treatment Of Chronic Heart Disease And Its Co-morbid Complications
Funder
National Health and Medical Research Council
Funding Amount
$5,793,580.00
Summary
Cardiovascular disease (CVD) and its associated additional disorders constitute major public health problems, especially given the rapidly ageing population which is increasingly affected by obesity and diabetes. This Program will explore novel therapies for the treatment of CVD and associated diseases, particularly focussing on chronic kidney disease, translating preliminary laboratory-based findings into clinical trials and then clinical and epidemiological findings into practice and policy.